Why Revance Therapeutics Stock Is Getting Crushed Today

Shares of the aesthetic and therapeutic company Revance Therapeutics (NASDAQ: RVNC) are in for a turbulent Monday. In premarket trading, the biopharma's shares sank by as much as 34% on heavy volume. After the closing bell last Friday, Revance announced that the U.S. Food and Drug Administration issued a complete response letter (a rejection) for the company's experimental treatment for moderate to severe glabellar (frown) lines called DaxibotulinumtoxinA for Injection.